Life Sciences and Medical Office Real Estate Outlook for Late 2026

By RadCRE Research · · Industry Insights

CBRE and Cushman & Wakefield track shifts across life sciences, European healthcare, and U.S. medical office development.

Capital Markets Shift Toward Healthcare and Life Sciences Facilities

Institutional interest in specialized healthcare real estate and research facilities remains an active focal point across global and domestic markets. In its midyear analysis for 2026, CBRE highlighted life sciences as a dedicated sector within its overarching U.S. Real Estate Market Outlook, tracking its interaction with macro trends across the broader economy, capital markets, and commercial office space [1]. Concurrently, cross-border research from CBRE’s October 2026 European Healthcare Real Estate report emphasizes steady institutional appetite for specialized health and care-oriented facilities, reflecting enduring demographic drivers and sustained operational demand [2].

New Construction Meets Adaptive Reuse Across Regional U.S. Hubs

On the asset level, transactions and leasing inventory underscore a bifurcation between ground-up Class A clinical facilities and conversion-ready existing structures. In suburban growth corridors, new specialized space is advancing to accommodate clinical outpatient demand. In Georgia, CBRE is marketing a 27,500-square-foot Class A medical office development located at 297 Rope Mill Road in Woodstock, addressing localized healthcare expansion [4].

Simultaneously, secondary markets continue to present value-add repositioning and adaptive reuse opportunities. In Des Moines, Iowa, a former medical office building situated at 7481 US-69 has been brought to the market by Cushman & Wakefield, offering an existing footprint for buyers targeting clinical reuse or alternative commercial repositioning [3]. These contrasting property profiles illustrate how capital is navigating between premium speculative developments and retrofitted medical assets.

RadCRE Perspective

"Underwriting specialized medical office buildings and life sciences facilities requires rigorous attention to clinical infrastructure, tenant credit quality, and long-term capital intensity. Whether evaluating Class A clinical developments or repositioning existing suburban assets, investors must align clear exit strategies with realistic replacement cost metrics," states Majid Radaei, Founder & Principal Broker of RadCRE.

As market dynamics evolve across specialized real estate asset classes, RadCRE leverages its institutional underwriting framework, powered by RadCRE.ai, to advise clients on capital markets execution, value-add acquisitions, and structured debt and equity strategies.

Tags: life sciences real estate outlook, medical office building investment, healthcare CRE underwriting, medical office leasing

Sources (published in the past 7 days):